Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children

Study Overview

The purpose of this study is to find out if the drug, Cabozantinib, is safe and tolerable in pediatric patients with refractory and/or recurrent high grade gliomas (HGG) who have previously received radiation therapy. We are also looking to see if the drug has an effect on the rate at which the tumor grows at 6 months.

Study Description

The purpose of this study is to test the safety, tolerability and efficacy of carbozantinib in refractory and/or recurrent pediatric high-grade gliomas in children who have previously received radiation therapy.

Additional Information

Participants will not be paid for their participation.

  • IRB Number: 1702306189 (IUSCC-0601)
  • Research Study Identifier: TX7541
  • Principal Investigator: Scott Coven

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.